GlassScriptPhysician profile
Hamza Viquar
NPI 1295296853
$1,208.69
in general payments reported to CMS, 2019-2025
16 companies · $19.59 in 2025
The $19.59 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $429 · 2023: $642 · 2024: $118 · 2025: $19.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $779.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $209.99 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $197.83 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $127.02 | 2022-2024 | Eliquis |
| Lilly USA, LLC | $107.08 | 2022-2023 | Emgality, Jardiance, Mounjaro |
| Amgen INC. | $97.42 | 2022-2023 | Repatha, Otezla, Prolia |
| Abbvie INC. | $92.09 | 2022-2025 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $79.25 | 2022-2023 | Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $61.81 | 2022 | |
| Jazz Pharmaceuticals INC. | $56.07 | 2022-2023 | |
| Pfizer INC. | $37.66 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $37.29 | 2022-2023 | Xarelto |
| Glaxosmithkline, LLC. | $27.25 | 2022-2023 | Arexvy, Shingrix |
| Axsome Therapeutics, INC. | $23.43 | 2024 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $21.42 | 2023 | Rexulti |
| Medtronic, INC. | $18.07 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $15.01 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamza Viquar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.